The comeback of hirudin as an antithrombotic agent.
Markwardt
F
F
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Germany.
D000818:Animals; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000009:adverse effects / Q000235:genetics / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D007865:Leeches / Q000737:chemistry; D011183:Postoperative Complications / Q000517:prevention & control; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000517:prevention & control
D005343:Fibrinolytic Agents; D006629:Hirudins; D011993:Recombinant Fusion Proteins; D006493:Heparin; D013917:Thrombin